Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20. 365(9472):1687-717. [Medline].
[Guideline] National Comprehensive Cancer Network (NCCN) Breast Cancer Panel. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 3.2018. NCCN.org. Available at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. 2018; Accessed: November 14, 2018.
Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003 Dec 3. 95(23):1758-64. [Medline].
Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 Jan 5. 97(1):30-9. [Medline].
Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006 Jul. 80(1):61-74. [Medline].
Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005 Dec 20. 23(36):9312-8. [Medline].
Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007 Nov 20. 25(33):5187-93. [Medline].
Goetz MP, Suman VJ, Hoskin TL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013 Jan 15. 19(2):500-7. [Medline]. [Full Text].
Wegman P, Vainikka L, Stål O, Nordenskjöld B, Skoog L, Rutqvist LE, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 2005. 7 (3):R284-90. [Medline].
[Guideline] Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 May. 103 (5):770-777. [Medline]. [Full Text].
Schroth W, Winter S, Mürdter T, Schaeffeler E, Eccles D, Eccles B, et al. Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. Front Pharmacol. 2017. 8:582. [Medline]. [Full Text].
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010 Dec. 11(12):1135-41. [Medline].
Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10. 25(5):486-92. [Medline].
Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012 Mar 21. 104(6):441-51. [Medline].
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012 Mar 21. 104(6):452-60. [Medline].
Brauch H, Schroth W, Goetz MP, Murdter TE, Winter S, Ingle JN. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2013 Jan 10. 31(2):176-80. [Medline].
Dieudonne AS, Lambrechts D, Wildiers H, Neven P. Why should results from metastatic trials no longer matter for early-stage disease?. J Clin Oncol. 2013 Jul 20. 31(21):2753. [Medline].
ITPC - International Tamoxifen Pharmacogenomics Consortium. PharmGKB. The Pharmacogenomics Knowledgebase. Available at https://www.pharmgkb.org/page/itpc. Accessed: October 22, 2015.
Province MA, Altman RB, Klein TE. Interpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics Consortium. Clin Pharmacol Ther. 2014 Aug. 96 (2):144-6. [Medline].
Province MA, Goetz MP, Brauch H, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther. 2014 Feb. 95 (2):216-27. [Medline].
Province MA, Klein TE, International Tamoxifen Pharmacogenomics Consortium. Re: CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst. 2014 Feb. 106 (2):djt379. [Medline].
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J. Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2013 Jul 15. [Medline].
Binkhorst L, Bannink M, de Bruijn P, Ruit J, Droogendijk H, van Alphen RJ, et al. Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Clin Pharmacokinet. 2016 Feb. 55 (2):249-55. [Medline]. [Full Text].
Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 Jan. 101 (1):113-21. [Medline].